Our focus is on chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), along with immune-mediated conditions like lupus. We pursue scientific advancements to tackle complex, unresolved challenges by targeting the fundamental biology and developing innovative drug modalities and combination therapies, aiming ultimately for disease modification and clinical remission.
We are pushing scientific boundaries by addressing core disease drivers with novel mechanisms and modalities, delivering the broadest spectrum of treatments designed to transform patient outcomes. Our extensive experience in developing therapies for tens of millions of patients has granted us invaluable insights into the unmet needs in managing respiratory and immune-mediated diseases, guiding our research efforts.
As scientific knowledge progresses, we engage larger patient populations and leverage rich datasets, including the industry’s largest genomic database, to enhance our understanding of novel imaging biomarkers that track disease progression and remission. The integration of machine learning and artificial intelligence accelerates the identification of new therapeutic targets for next-generation treatments. Our patient-centered clinical trials incorporate digital health solutions and innovative study endpoints to achieve improved outcomes—moving beyond symptom control to demonstrate true disease modification and remission. Additionally, we are innovating trial design and execution to create smarter, shorter, and more efficient studies.
